FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2795363050> ?p ?o ?g. }

• W2795363050 endingPage "2894" @default.
• W2795363050 startingPage "2885" @default.
• W2795363050 abstract "Sirolimus appears to protect against cytomegalovirus (CMV) in organ transplant recipients. The effect of this drug in allogeneic hematopoietic stem cell transplantation recipients remains unexplored. By means of multivariate continuous-time Markov model analyses, we identified 3 independent covariates that significantly impacted the risk of CMV DNAemia: recipient/donor CMV serostatus, tacrolimus exposure, and sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had a significantly higher probability of having detectable CMV DNAemia. Increasing the tacrolimus trough concentration from 0 to 16 ng/mL increased the probability of patients having detectable CMV DNAemia by 40% (from 40% to 80%), whereas this probability decreased by 25% (from 40% to 15%) when trough concentrations of sirolimus increased from 0 to 16 ng/mL. Sensitivity analysis showed that sirolimus exposure between 0 and 6 ng/mL has no or negligible effect on CMV DNAemia, but levels >8 ng/mL significantly decreased the number of detectable CMV DNAemia cases (the risk ratios decreased from 0.68 to 0.21 when whole blood sirolimus concentrations changed from 8 to 18 ng/mL, P < .01). In conclusion, we used a pharmacometric statistical tool to provide the first clinical evidence that fewer CMV DNAemia events become detectable as sirolimus exposure increases. Sirolimus appears to protect against cytomegalovirus (CMV) in organ transplant recipients. The effect of this drug in allogeneic hematopoietic stem cell transplantation recipients remains unexplored. By means of multivariate continuous-time Markov model analyses, we identified 3 independent covariates that significantly impacted the risk of CMV DNAemia: recipient/donor CMV serostatus, tacrolimus exposure, and sirolimus exposure. CMV-seropositive recipients with CMV-seronegative donors had a significantly higher probability of having detectable CMV DNAemia. Increasing the tacrolimus trough concentration from 0 to 16 ng/mL increased the probability of patients having detectable CMV DNAemia by 40% (from 40% to 80%), whereas this probability decreased by 25% (from 40% to 15%) when trough concentrations of sirolimus increased from 0 to 16 ng/mL. Sensitivity analysis showed that sirolimus exposure between 0 and 6 ng/mL has no or negligible effect on CMV DNAemia, but levels >8 ng/mL significantly decreased the number of detectable CMV DNAemia cases (the risk ratios decreased from 0.68 to 0.21 when whole blood sirolimus concentrations changed from 8 to 18 ng/mL, P < .01). In conclusion, we used a pharmacometric statistical tool to provide the first clinical evidence that fewer CMV DNAemia events become detectable as sirolimus exposure increases." @default.
• W2795363050 created "2018-04-06" @default.
• W2795363050 creator A5022860197 @default.
• W2795363050 creator A5028478931 @default.
• W2795363050 creator A5054250233 @default.
• W2795363050 creator A5057536435 @default.
• W2795363050 creator A5059689286 @default.
• W2795363050 creator A5065232101 @default.
• W2795363050 creator A5070420697 @default.
• W2795363050 creator A5075480861 @default.
• W2795363050 creator A5075722788 @default.
• W2795363050 date "2018-12-01" @default.
• W2795363050 modified "2023-10-18" @default.
• W2795363050 title "Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation" @default.
• W2795363050 cites W1504906459 @default.
• W2795363050 cites W1505741639 @default.
• W2795363050 cites W1973617793 @default.
• W2795363050 cites W1978951845 @default.
• W2795363050 cites W1989700483 @default.
• W2795363050 cites W1994212426 @default.
• W2795363050 cites W2011660868 @default.
• W2795363050 cites W2038981426 @default.
• W2795363050 cites W2039673714 @default.
• W2795363050 cites W2039824458 @default.
• W2795363050 cites W2042269427 @default.
• W2795363050 cites W2046433603 @default.
• W2795363050 cites W2047260189 @default.
• W2795363050 cites W2055981604 @default.
• W2795363050 cites W2061849028 @default.
• W2795363050 cites W2064876347 @default.
• W2795363050 cites W2066937567 @default.
• W2795363050 cites W2069288697 @default.
• W2795363050 cites W2077349622 @default.
• W2795363050 cites W2105193766 @default.
• W2795363050 cites W2118802947 @default.
• W2795363050 cites W2122664355 @default.
• W2795363050 cites W2135611431 @default.
• W2795363050 cites W2137112042 @default.
• W2795363050 cites W2139591514 @default.
• W2795363050 cites W2141010787 @default.
• W2795363050 cites W2147938492 @default.
• W2795363050 cites W2157582689 @default.
• W2795363050 cites W2161697105 @default.
• W2795363050 cites W2167218562 @default.
• W2795363050 cites W2192795845 @default.
• W2795363050 cites W2277663056 @default.
• W2795363050 cites W2312658128 @default.
• W2795363050 cites W2395266396 @default.
• W2795363050 cites W2425100693 @default.
• W2795363050 cites W2493042425 @default.
• W2795363050 cites W2524753328 @default.
• W2795363050 cites W2600761575 @default.
• W2795363050 cites W2604291021 @default.
• W2795363050 cites W2610988738 @default.
• W2795363050 cites W40694895 @default.
• W2795363050 cites W4237375795 @default.
• W2795363050 doi "https://doi.org/10.1111/ajt.14754" @default.
• W2795363050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29603596" @default.
• W2795363050 hasPublicationYear "2018" @default.
• W2795363050 type Work @default.
• W2795363050 sameAs 2795363050 @default.
• W2795363050 citedByCount "21" @default.
• W2795363050 countsByYear W27953630502019 @default.
• W2795363050 countsByYear W27953630502020 @default.
• W2795363050 countsByYear W27953630502021 @default.
• W2795363050 countsByYear W27953630502022 @default.
• W2795363050 countsByYear W27953630502023 @default.
• W2795363050 crossrefType "journal-article" @default.
• W2795363050 hasAuthorship W2795363050A5022860197 @default.
• W2795363050 hasAuthorship W2795363050A5028478931 @default.
• W2795363050 hasAuthorship W2795363050A5054250233 @default.
• W2795363050 hasAuthorship W2795363050A5057536435 @default.
• W2795363050 hasAuthorship W2795363050A5059689286 @default.
• W2795363050 hasAuthorship W2795363050A5065232101 @default.
• W2795363050 hasAuthorship W2795363050A5070420697 @default.
• W2795363050 hasAuthorship W2795363050A5075480861 @default.
• W2795363050 hasAuthorship W2795363050A5075722788 @default.
• W2795363050 hasBestOaLocation W27953630501 @default.
• W2795363050 hasConcept C126322002 @default.
• W2795363050 hasConcept C142462285 @default.
• W2795363050 hasConcept C203014093 @default.
• W2795363050 hasConcept C2522874641 @default.
• W2795363050 hasConcept C2776409557 @default.
• W2795363050 hasConcept C2776535787 @default.
• W2795363050 hasConcept C2777408962 @default.
• W2795363050 hasConcept C2777732132 @default.
• W2795363050 hasConcept C2777921159 @default.
• W2795363050 hasConcept C2779820661 @default.
• W2795363050 hasConcept C2780727368 @default.
• W2795363050 hasConcept C2909675724 @default.
• W2795363050 hasConcept C2911091166 @default.
• W2795363050 hasConcept C71924100 @default.
• W2795363050 hasConcept C90924648 @default.
• W2795363050 hasConceptScore W2795363050C126322002 @default.
• W2795363050 hasConceptScore W2795363050C142462285 @default.
• W2795363050 hasConceptScore W2795363050C203014093 @default.
• W2795363050 hasConceptScore W2795363050C2522874641 @default.
• W2795363050 hasConceptScore W2795363050C2776409557 @default.

• next